Drugs / NKTR-262
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03435640 | Mar 2018 → May 2022 | colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, melanoma +3 | Nektar Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2020-11-11 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
BEMPEG/NKTR-262 treatment produces a higher fraction of activated tumor antigen-specific cytotoxic CD8 T cells systemically, correlating with superior anti-tumor efficacy relative to BEMPEG combined with radiotherapy (RT). |
| 2019-03-01 | Nektar Therapeutics | Results Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting nektar.com ↗
The early data from REVEAL demonstrate that a comprehensive approach to activating the body's immune system can drive abscopal anti-tumor responses even in the absence of a checkpoint inhibitor. |
| 2018-11-09 | Nektar Therapeutics | Results Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
When combined with these treatments, NKTR-214 showed the potential to lead to tumor clearance and tumor specific immunologic memory. |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKTR-262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03435640 ↗ |
| Action | Activate | “NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8” NCT03435640 ↗ |
| Modality | Small molecule | “NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8” NCT03435640 ↗ |
| Route | Other | “intratumoral (IT) injections of NKTR-262” NCT03435640 ↗ |
| Target | TLR7 | “NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity” PMID 35444059 ↗ Apr 2022 |